Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03796364
Other study ID # XQonc-008
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 1, 2018
Est. completion date July 31, 2020

Study information

Verified date February 2024
Source Xinqiao Hospital of Chongqing
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To verify the efficacy and safety of endostatin in the treatment of SRILI(symptomatic radiation-induced lung injury) and fibrosis. The results of this study are expected to be a new clinical strategy for the treatment of radiation pneumonia and fibrosis.


Description:

Radiotherapy is an important treatment of lung cancer, symptomatic radiation-induced lung injury (SRILR) is the most common complications. In view of the important role of endostatin in inhibiting angiogenesis and pro-inflammatory factors, Combined with randomized controlled clinical study and small sample clinical exploration, the investigators concluded that endostatin is a new clinical technique for the treatment of radiation pneumonia(RP) and radiation fibrosis(RF), which can reduce the recurrence rate of RP. In order to verify the efficacy and safety of endostatin in the treatment of SRILI and fibrosis, the investigators intend to use a prospective, randomized, multicenter clinical trial to classify unresectable phase III-IV Non-small cell lung cancer(NSCLC) patients with SRILI above grade 2 into the control group (standard SRILI treatment) and observation group (Endostar® plus standard treatment) on a 1:1 randomized basis. The results of this study are expected to be a new clinical strategy for the treatment of radiation pneumonia and fibrosis.


Recruitment information / eligibility

Status Completed
Enrollment 126
Est. completion date July 31, 2020
Est. primary completion date May 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients defined as NSCLC who could not be operated on, phase III-IV; 2. EOCG PS: 0-3; 3. The clinical diagnosis is RILI, with grade 2-3; 4. No major organ dysfunction, such as heart failure and chronic obstructive pneumonia; 5. No Endostar use contraindication; 6. Volunteer to participate, good compliance, can cooperate with the test observation, and sign a written informed consent. Exclusion Criteria: 1. Patient compliance is poor and violates the test regulations; 2. Major organ dysfunction like liver and kidney occurs, such as myocardial infarction, angina pectoris, liver transaminase increased significantly; 3. Hemorrhage or thrombus occurs, anticoagulant medication is required; 4. Serious adverse drug reactions occur during treatment; 5. The patient asked to be withdrawn from the trial; 6. Other antiangiogenic drugs were used.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Endostar
Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
standard SRILI treatment
Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.

Locations

Country Name City State
China Xinqiao Hospital of Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary recrudescence rate of RP(Radiation pneumonitis) Patients in the observation group were treated with routine radiation pneumonia and Endostar.
Patients in the control group were treated with current routine radiation pneumonia. Chest CT were assessed for recrudescence rate of RP at week 12. The calculation method is: number of relapse cases / total number of treatment groups × 100%; RP is classified according to CTCAE4.0, patients with grade 2 or higher are improved after treatment, and those who are assessed to be grade 2 or higher are considered recrudescence). Results are expressed as a percentage.
at week12
Secondary remission rate of RP Patients in the observation group were treated with routine radiation pneumonia and Endostar. Results are expressed as a percentage.
Patients in the control group were treated with current routine radiation pneumonia. Chest CT were assessed for remission rate of RP at week 12.
at week 12
Secondary incidence rate of RF(Radioactive fibrosis) Patients in the observation group were treated with routine radiation pneumonia and Endostar.
Patients in the control group were treated with current routine radiation pneumonia. Chest CT were assessed for incidence rate of RF at week 12.
at week 12
See also
  Status Clinical Trial Phase
Recruiting NCT02490319 - Study on the Biological Prediction Models of Radiation Pneumonitis
Recruiting NCT03803787 - Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients Phase 2
Not yet recruiting NCT04632342 - Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients Phase 2
Recruiting NCT05365802 - FAPI PET for Lung Fibrosis Early Phase 1
Completed NCT01754909 - Mitigation of Radiation Pneumonitis and Fibrosis Phase 2
Recruiting NCT05189496 - Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis N/A
Completed NCT01745484 - Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation N/A
Enrolling by invitation NCT02809456 - Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients Phase 2
Recruiting NCT00155909 - Risk Factors of Radiation Pneumonitis N/A
Recruiting NCT06069115 - Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Completed NCT04863027 - Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
Not yet recruiting NCT02296281 - Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury Phase 2
Completed NCT03462524 - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology N/A
Recruiting NCT05448703 - A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
Recruiting NCT06079931 - The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia Phase 2
Recruiting NCT04676828 - Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer N/A
Recruiting NCT02735746 - Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis